JPH07504888A - CDw52−多発性硬化症の治療のための特異抗体 - Google Patents
CDw52−多発性硬化症の治療のための特異抗体Info
- Publication number
- JPH07504888A JPH07504888A JP5509973A JP50997393A JPH07504888A JP H07504888 A JPH07504888 A JP H07504888A JP 5509973 A JP5509973 A JP 5509973A JP 50997393 A JP50997393 A JP 50997393A JP H07504888 A JPH07504888 A JP H07504888A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- treatment
- multiple sclerosis
- campath
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (15)
- 1.CDw52抗原を認識する抗体の、多発性硬化症の治療のための医薬の製造 への使用。
- 2.抗体がマウスもしくはラット抗体由来のCDRを含むヒト化抗体であり、該 CDRが1種以上のヒト抗体由来のフレームワーク領域および定常ドメインと結 合している請求の範囲第1項記載の使用。
- 3.抗体がCAMPATH−1Hである請求の範囲第2項記載の方法。
- 4.治療には、1日当り1ないし10mgの投与量で1ないし30日の期間、患 者に毎日投与することが含まれる請求の範囲第1項ないし第3項のいずれか1項 に記載の使用。
- 5.治療にはステロイドの投与が含まれる請求の範囲第4項記載の使用。
- 6.CDw52抗原を認識する抗体を活性成分として含有する、多発性硬化症を 治療するための治療薬。
- 7.抗体がマウスもしくはラット抗体由来のCDRを含むヒト化抗体であり、該 CDRが1種以上のヒト抗体由来のフレームワーク領域および定常ドメインと結 合している請求の範囲第6項記載の治療薬。
- 8.抗体がCAMPATH−1Hである請求の範囲第7項記載の治療薬。
- 9.抗体の1日投与量が、1ないし30日の期間、1日当り1ないし10mgで ある請求の範囲第6項ないし第8項のいずれか1項に記載の治療薬。
- 10.治療にはステロイドの投与が含まれる請求の範囲第6項ないし第9項のい ずれか1項に記載の治療薬。
- 11.多発性硬化症に罹患したヒト患者の治療方法であってCOw52抗原を認 識する抗体の有効量を該患者に投与することを具備する方法。
- 12.抗体がマウスもしくはラット抗体由来のCORを含むヒト化抗体であり、 該CDRが1種以上のヒト抗体由来のフレームワーク領域および定常ドメインと 結合している請求の範囲第11項記載の方法。
- 13.抗体がCAMPATH−1Hである請求の範囲第12項記載の方法。
- 14.1日当り1ないし10mgで1ないし30日の期間、抗体を毎日投与する ことを具備する請求の範囲第11項ないし第13項のいずれか1項記載の方法。
- 15.有効量のステロイドを投与することを包含する請求の範囲第11項ないし 第14項のいずれか1項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9125768.3 | 1991-12-04 | ||
GB919125768A GB9125768D0 (en) | 1991-12-04 | 1991-12-04 | Therapeutic method |
PCT/GB1992/002252 WO1993010817A1 (en) | 1991-12-04 | 1992-12-04 | CDw52-SPECIFIC ANTIBODY FOR TREATMENT OF MULTIPLE SCLEROSIS |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH07504888A true JPH07504888A (ja) | 1995-06-01 |
JP3383303B2 JP3383303B2 (ja) | 2003-03-04 |
Family
ID=10705671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50997393A Expired - Lifetime JP3383303B2 (ja) | 1991-12-04 | 1992-12-04 | CDw52−多発性硬化症の治療のための特異抗体 |
Country Status (18)
Country | Link |
---|---|
US (2) | US6120766A (ja) |
EP (1) | EP0616537B1 (ja) |
JP (1) | JP3383303B2 (ja) |
KR (1) | KR100271333B1 (ja) |
AT (1) | ATE177011T1 (ja) |
AU (1) | AU3089692A (ja) |
CA (1) | CA2124964C (ja) |
DE (1) | DE69228556T2 (ja) |
DK (1) | DK0616537T3 (ja) |
ES (1) | ES2128363T3 (ja) |
GB (1) | GB9125768D0 (ja) |
GR (1) | GR3029683T3 (ja) |
HK (1) | HK1011618A1 (ja) |
IL (1) | IL103981A (ja) |
MX (1) | MX9207032A (ja) |
MY (1) | MY111961A (ja) |
WO (1) | WO1993010817A1 (ja) |
ZA (1) | ZA929446B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010503631A (ja) * | 2006-09-13 | 2010-02-04 | アルカフロイ マネージメント ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト | カンパス−1H(Campath−1H)による多発性硬化症(MS)治療 |
Families Citing this family (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9022543D0 (en) * | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
GB9125768D0 (en) * | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
GB9603507D0 (en) | 1996-02-20 | 1996-04-17 | Isis Innovation | Antibody variants |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
US7541184B2 (en) | 2000-02-24 | 2009-06-02 | Invitrogen Corporation | Activation and expansion of cells |
AU2002360696A1 (en) * | 2001-12-21 | 2003-07-30 | Ilex Oncology, Inc. | Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis |
JP2005517025A (ja) | 2002-02-08 | 2005-06-09 | エクサイト セラピーズ, インコーポレイテッド | 免疫学的欠損を有する患者において免疫応答性を回復するための、組成物および方法 |
WO2004003142A2 (en) | 2002-06-28 | 2004-01-08 | Xcyte Therapies, Inc. | Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
WO2004104185A1 (en) * | 2003-05-08 | 2004-12-02 | Xcyte Therapies, Inc. | Generation and isolation of antigen-specific t cells |
EP1663308A1 (en) * | 2003-09-22 | 2006-06-07 | Xcyte Therapies, Inc | Compositions and methods to accelerate hematologic recovery |
DK1694706T3 (da) | 2003-11-01 | 2012-07-16 | Merck Patent Gmbh | Modificeret anti-CD52-antistof |
WO2007120834A2 (en) | 2006-04-13 | 2007-10-25 | Peptimmune, Inc. | Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability |
EP1854810A1 (en) | 2006-05-09 | 2007-11-14 | PanGenetics B.V. | Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody |
US9498528B2 (en) | 2006-09-13 | 2016-11-22 | Genzyme Corporation | Treatment of multiple sclerosis (MS) |
JP5662684B2 (ja) * | 2007-02-16 | 2015-02-04 | ジェンザイム コーポレーション | 甲状腺障害リスクの同定方法 |
US8962273B2 (en) * | 2007-05-11 | 2015-02-24 | Genzyme Corporation | Methods of producing a secreted protein |
MX342907B (es) | 2009-05-13 | 2016-10-17 | Genzyme Corp * | El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus. |
US8617554B2 (en) * | 2009-05-13 | 2013-12-31 | Genzyme Corporation | Anti-human CD52 immunoglobulins |
DK2649086T3 (en) | 2010-12-09 | 2017-09-18 | Univ Pennsylvania | USING CHEMICAL ANTIGEN RECEPTOR-MODIFIED T-CELLS TO TREAT CANCER |
CA2824997C (en) | 2011-01-18 | 2023-01-17 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
KR20140045533A (ko) | 2011-07-29 | 2014-04-16 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 스위치 공자극 수용체 |
EA201490636A1 (ru) | 2011-09-16 | 2014-08-29 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Сконструированные с помощью рнк t-клетки для лечения злокачественных новообразований |
US9272002B2 (en) | 2011-10-28 | 2016-03-01 | The Trustees Of The University Of Pennsylvania | Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
EP2773651B1 (en) | 2011-11-03 | 2020-12-23 | The Trustees of the University of Pennsylvania | Isolated b7-h4 specific compositions and methods of use thereof |
WO2013070468A1 (en) | 2011-11-08 | 2013-05-16 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
KR20140127829A (ko) | 2012-02-22 | 2014-11-04 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 2세대 키메라 항원 수용체에서 cd2 시그널링 도메인의 용도 |
EA201491574A1 (ru) | 2012-02-22 | 2014-12-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Применение car, основанных на icos, для усиления противоопухолевой активности и длительного сохранения car |
EA201590208A1 (ru) | 2012-07-13 | 2015-11-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Усиление активности т-клеток car путем совместного введения биспецифического антитела |
FI4019041T3 (fi) | 2012-07-13 | 2023-04-03 | Univ Pennsylvania | Car:ien antitumoraalisen aktiivisuuden toksisuuden hallinta |
KR20210149195A (ko) | 2012-07-13 | 2021-12-08 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 형질도입된 t 세포의 투여 적합성을 평가하는 방법 |
WO2014055771A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
US9446105B2 (en) | 2013-03-15 | 2016-09-20 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor specific for folate receptor β |
CN105518018B (zh) * | 2013-03-15 | 2020-04-03 | 细胞基因公司 | 修饰的t淋巴细胞 |
AR095199A1 (es) | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
US10640569B2 (en) | 2013-12-19 | 2020-05-05 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
WO2015112626A1 (en) | 2014-01-21 | 2015-07-30 | June Carl H | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
ES2939760T3 (es) | 2014-03-15 | 2023-04-26 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico para antígenos |
IL280215B (en) | 2014-04-07 | 2022-07-01 | Novartis Ag | Cancer treatment using a chimeric receptor antigen (car) against cd19 |
US10301370B2 (en) | 2014-05-02 | 2019-05-28 | The Trustees Of The University Of Pennsylvania | Compositions and methods of chimeric autoantibody receptor T cells |
WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
JP6831777B2 (ja) | 2014-07-21 | 2021-02-17 | ノバルティス アーゲー | Cd33キメラ抗原受容体を使用する癌の処置 |
EP4205749A1 (en) | 2014-07-31 | 2023-07-05 | Novartis AG | Subset-optimized chimeric antigen receptor-containing cells |
US10851149B2 (en) | 2014-08-14 | 2020-12-01 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using GFR α-4 chimeric antigen receptor |
CN106973568B (zh) | 2014-10-08 | 2021-07-23 | 诺华股份有限公司 | 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途 |
JP6884697B2 (ja) | 2014-10-31 | 2021-06-09 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | T細胞を刺激および拡大する組成物および方法 |
JP6879910B2 (ja) | 2014-10-31 | 2021-06-02 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Cart細胞における遺伝子発現の改変およびその使用 |
US20180334490A1 (en) | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
EP3250681B1 (en) | 2015-01-31 | 2023-05-03 | The Trustees of the University of Pennsylvania | Compositions and methods for t cell delivery of therapeutic molecules |
US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
EP3730515B1 (en) | 2015-02-16 | 2023-07-26 | The Trustees of the University of Pennsylvania | A fully-human t cell receptor specific for the 369-377 epitope derived from the her2/neu (erbb2) receptor protein |
AU2016228080B2 (en) | 2015-03-02 | 2020-11-12 | Innovative Cellular Therapeutics Holdings, Ltd. | Reducing immune tolerance induced by PD-L1 |
EP3280795B1 (en) | 2015-04-07 | 2021-03-24 | Novartis AG | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
ES2948133T3 (es) | 2015-04-17 | 2023-08-31 | Novartis Ag | Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico |
WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
PL3298033T5 (pl) | 2015-05-18 | 2023-10-30 | TCR2 Therapeutics Inc. | Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych |
EP3297672B1 (en) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
WO2017040324A1 (en) | 2015-08-28 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
WO2017040195A1 (en) | 2015-08-28 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
CN116334205A (zh) | 2015-09-03 | 2023-06-27 | 诺华股份有限公司 | 预测细胞因子释放综合征的生物标志物 |
CN108138148B (zh) | 2015-10-08 | 2021-10-29 | 上海斯丹赛生物技术有限公司 | T细胞的激活和扩增 |
WO2017091786A1 (en) | 2015-11-23 | 2017-06-01 | Novartis Ag | Optimized lentiviral transfer vectors and uses thereof |
MA44140A (fr) | 2015-12-22 | 2021-05-19 | Dana Farber Cancer Inst Inc | Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse |
SG11201807489PA (en) | 2016-03-04 | 2018-09-27 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
EP3988111A1 (en) | 2016-04-01 | 2022-04-27 | Innovative Cellular Therapeutics Holdings, Ltd. | Use of chimeric antigen receptor modified cells to treat cancer |
CN109328230A (zh) | 2016-04-15 | 2019-02-12 | 宾夕法尼亚大学董事会 | 嵌合同种异体抗原受体t细胞的组合物和方法 |
JP7101621B2 (ja) | 2016-05-20 | 2022-07-15 | ハープーン セラピューティクス,インク. | 単一ドメイン血清アルブミン結合タンパク質 |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
KR20190057275A (ko) | 2016-07-18 | 2019-05-28 | 헬릭스 바이오파마 코포레이션 | 암을 치료하기 위한 암배아 항원 관련 세포 부착 분자 6에 대한 car 면역 세포 |
CA3032498A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
CN109689686B (zh) | 2016-10-07 | 2020-08-25 | T细胞受体治疗公司 | 使用融合蛋白进行t细胞受体重编程的组合物和方法 |
TW202340473A (zh) | 2016-10-07 | 2023-10-16 | 瑞士商諾華公司 | 利用嵌合抗原受體之癌症治療 |
EP4338799A3 (en) | 2016-10-18 | 2024-06-05 | Regents of the University of Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
CN110177803A (zh) | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重新编程的组合物和方法 |
CN110198955A (zh) | 2016-11-23 | 2019-09-03 | 哈普恩治疗公司 | 前列腺特异性膜抗原结合蛋白质 |
US10844134B2 (en) | 2016-11-23 | 2020-11-24 | Harpoon Therapeutics, Inc. | PSMA targeting trispecific proteins and methods of use |
WO2018111340A1 (en) | 2016-12-16 | 2018-06-21 | Novartis Ag | Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells |
EP3558348A1 (en) | 2016-12-21 | 2019-10-30 | TCR2 Therapeutics Inc. | Engineered t cells for the treatment of cancer |
EP3609536B1 (en) | 2017-01-05 | 2022-03-09 | Innovative Cellular Therapeutics Holdings, Ltd. | Humanized anti-cd19 antibody and use thereof with chimeric antigen receptor |
EP3589662A4 (en) | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | INDUCTIBLE MONOVALENT ANTIGBINDING PROTEIN |
WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
AU2018265856B2 (en) | 2017-05-12 | 2023-04-27 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
CA3063362A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Msln targeting trispecific proteins and methods of use |
WO2018232020A1 (en) | 2017-06-13 | 2018-12-20 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
CA3078472A1 (en) | 2017-10-06 | 2019-04-11 | Oslo Universitetssykehus Hf | Chimeric antigen receptors |
SG11202003341UA (en) | 2017-10-13 | 2020-05-28 | Harpoon Therapeutics Inc | B cell maturation antigen binding proteins |
CR20200196A (es) | 2017-10-13 | 2020-06-05 | Harpoon Therapeutics Inc | Proteínas trispecìficas y mètodos de uso |
JP2021502979A (ja) | 2017-11-15 | 2021-02-04 | ノバルティス アーゲー | Bcmaターゲティングキメラ抗原受容体、cd19ターゲティングキメラ抗原受容体及び併用療法 |
WO2019129851A1 (en) | 2017-12-29 | 2019-07-04 | Cellectis | Method for improving production of car t cells |
EP3737408A1 (en) | 2018-01-08 | 2020-11-18 | Novartis AG | Immune-enhancing rnas for combination with chimeric antigen receptor therapy |
EP3746116A1 (en) | 2018-01-31 | 2020-12-09 | Novartis AG | Combination therapy using a chimeric antigen receptor |
EP3752203A1 (en) | 2018-02-13 | 2020-12-23 | Novartis AG | Chimeric antigen receptor therapy in combination with il-15r and il15 |
EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
JP2021526795A (ja) | 2018-06-05 | 2021-10-11 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 筋特異的キナーゼキメラ自己受容体細胞の組成物および方法 |
CA3100724A1 (en) | 2018-06-13 | 2019-12-19 | Novartis Ag | B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof |
WO2019241549A1 (en) | 2018-06-15 | 2019-12-19 | A2 Biotherapeutics, Inc. | Foxp3-expressing car-t regulatory cells |
EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
JP7227374B2 (ja) | 2018-08-13 | 2023-02-21 | ルートパス・ジェノミクス,インコーポレーテッド | 対合二分免疫受容体ポリヌクレオチドのハイスループットクローニングおよびその適用 |
US20210253666A1 (en) | 2018-08-30 | 2021-08-19 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
EP3856782A1 (en) | 2018-09-28 | 2021-08-04 | Novartis AG | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
US20220047633A1 (en) | 2018-09-28 | 2022-02-17 | Novartis Ag | Cd22 chimeric antigen receptor (car) therapies |
WO2020092455A2 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
KR102588292B1 (ko) | 2019-03-15 | 2023-10-11 | 카티전 테라퓨틱스, 인코포레이티드 | 항-bcma 키메라 항원 수용체 |
SG11202110956RA (en) | 2019-04-05 | 2021-10-28 | Rootpath Genomics Inc | Compositions and methods for t-cell receptor gene assembly |
WO2021035170A1 (en) | 2019-08-21 | 2021-02-25 | Precision Biosciences, Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
MX2022006365A (es) | 2019-11-26 | 2022-06-22 | Novartis Ag | Receptores de antigeno quimerico cd19 y cd22 y usos de los mismos. |
JP2023527609A (ja) | 2020-02-21 | 2023-06-30 | ハープーン セラピューティクス,インク. | Flt3結合タンパク質および使用方法 |
IL298473A (en) | 2020-06-11 | 2023-01-01 | Novartis Ag | zbtb32 inhibitors and uses thereof |
WO2022104061A1 (en) | 2020-11-13 | 2022-05-19 | Novartis Ag | Combination therapies with chimeric antigen receptor (car)-expressing cells |
WO2022254337A1 (en) | 2021-06-01 | 2022-12-08 | Novartis Ag | Cd19 and cd22 chimeric antigen receptors and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989007452A1 (en) * | 1988-02-12 | 1989-08-24 | Medical Research Council | Improvements in or relating to antibodies |
GB9022543D0 (en) * | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
GB9022547D0 (en) * | 1990-10-17 | 1990-11-28 | Wellcome Found | Purified immunoglobulin |
GB9125768D0 (en) * | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
-
1991
- 1991-12-04 GB GB919125768A patent/GB9125768D0/en active Pending
-
1992
- 1992-12-04 MY MYPI92002238A patent/MY111961A/en unknown
- 1992-12-04 DK DK92924783T patent/DK0616537T3/da active
- 1992-12-04 AT AT92924783T patent/ATE177011T1/de active
- 1992-12-04 EP EP92924783A patent/EP0616537B1/en not_active Expired - Lifetime
- 1992-12-04 MX MX9207032A patent/MX9207032A/es unknown
- 1992-12-04 DE DE69228556T patent/DE69228556T2/de not_active Expired - Lifetime
- 1992-12-04 ES ES92924783T patent/ES2128363T3/es not_active Expired - Lifetime
- 1992-12-04 IL IL103981A patent/IL103981A/xx not_active IP Right Cessation
- 1992-12-04 US US08/244,316 patent/US6120766A/en not_active Expired - Lifetime
- 1992-12-04 WO PCT/GB1992/002252 patent/WO1993010817A1/en active IP Right Grant
- 1992-12-04 AU AU30896/92A patent/AU3089692A/en not_active Abandoned
- 1992-12-04 KR KR1019940701885A patent/KR100271333B1/ko not_active IP Right Cessation
- 1992-12-04 JP JP50997393A patent/JP3383303B2/ja not_active Expired - Lifetime
- 1992-12-04 ZA ZA929446A patent/ZA929446B/xx unknown
- 1992-12-04 CA CA002124964A patent/CA2124964C/en not_active Expired - Lifetime
-
1998
- 1998-12-07 HK HK98112902A patent/HK1011618A1/xx not_active IP Right Cessation
-
1999
- 1999-03-12 GR GR990400767T patent/GR3029683T3/el unknown
-
2004
- 2004-09-13 US US10/938,874 patent/US20050118172A1/en not_active Abandoned
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010503631A (ja) * | 2006-09-13 | 2010-02-04 | アルカフロイ マネージメント ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト | カンパス−1H(Campath−1H)による多発性硬化症(MS)治療 |
JP2014058555A (ja) * | 2006-09-13 | 2014-04-03 | Alcafleu Management Gmbh & Co Kg | カンパス−1H(Campath−1H)による多発性硬化症(MS)治療 |
JP2016175929A (ja) * | 2006-09-13 | 2016-10-06 | アルカフロイ マネージメント ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト | カンパス−1H(Campath−1H)による多発性硬化症(MS)治療 |
JP2018024655A (ja) * | 2006-09-13 | 2018-02-15 | アルカフロイ マネージメント ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト | カンパス−1H(Campath−1H)による多発性硬化症(MS)治療 |
Also Published As
Publication number | Publication date |
---|---|
MY111961A (en) | 2001-03-31 |
KR100271333B1 (ko) | 2000-11-01 |
JP3383303B2 (ja) | 2003-03-04 |
AU3089692A (en) | 1993-06-28 |
ATE177011T1 (de) | 1999-03-15 |
HK1011618A1 (en) | 1999-07-16 |
ZA929446B (en) | 1993-08-19 |
DK0616537T3 (da) | 1999-09-27 |
GB9125768D0 (en) | 1992-02-05 |
IL103981A (en) | 1997-07-13 |
EP0616537B1 (en) | 1999-03-03 |
GR3029683T3 (en) | 1999-06-30 |
WO1993010817A1 (en) | 1993-06-10 |
MX9207032A (es) | 1993-07-01 |
EP0616537A1 (en) | 1994-09-28 |
DE69228556T2 (de) | 1999-07-08 |
ES2128363T3 (es) | 1999-05-16 |
US20050118172A1 (en) | 2005-06-02 |
CA2124964A1 (en) | 1993-06-10 |
DE69228556D1 (de) | 1999-04-08 |
US6120766A (en) | 2000-09-19 |
CA2124964C (en) | 2005-03-15 |
IL103981A0 (en) | 1993-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH07504888A (ja) | CDw52−多発性硬化症の治療のための特異抗体 | |
DE69734317T2 (de) | Anti-tnf antikörper / tnf rezeptor und methotrexat zur behandlung von autoimmunkrankheiten | |
US7629311B2 (en) | Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers | |
US8236306B2 (en) | Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers | |
RU2607022C2 (ru) | Способы и композиции для лечения волчанки | |
RU2472526C2 (ru) | Фармацевтическая композиция, содержащая анти-cd6 моноклональное антитело, пригодная для диагностики и лечения ревматоидного артрита | |
Kanwar | Anti-inflammatory immunotherapy for multiple sclerosis/experimental autoimmune encephalomyelitis (EAE) disease | |
CA2473754C (en) | Treatment of ms with goat serum | |
PT1737490E (pt) | Processos de tratamento da aterosclerose | |
AU2003202093A1 (en) | Treatment of MS with goat serum | |
JP3535155B2 (ja) | 関節のT細胞介在炎症の治療のためのCDw52特異抗体 | |
DE202021004005U1 (de) | Ofatumumab zur Behandlung von MS unter Beibehaltung des IgG im Serum | |
KR20220062025A (ko) | 요법 교체에 의한 rms의 치료 | |
WO2021018191A1 (zh) | Il-17拮抗剂治疗自身免疫疾病的方法 | |
Marjanovic et al. | Rasmussen syndrome and long-term response to thalidomide | |
JP3973360B2 (ja) | 関節リウマチまたは皮膚疾患の処置に使用するためのcd25結合分子 | |
CN112912140A (zh) | 用于治疗化脓性汗腺炎的pan-elr+cxc趋化因子抗体 | |
WO2022075476A1 (en) | Method for treating ox40 related disease | |
CA2060384C (en) | A pharmaceutical composition containing an antibody recognizing the cdw52 antigen | |
JP2024516019A (ja) | 抗baffr抗体を使用する全身性エリテマトーデスのための治療 | |
WO2004006950A2 (de) | Verwendung von cd152, pd-1 und btla zur behandlung von autoimmunkrankheiten und entzündungen | |
US20110086046A1 (en) | Treatment of MS with goat serum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071220 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081220 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091220 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101220 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101220 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111220 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111220 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121220 Year of fee payment: 10 |
|
EXPY | Cancellation because of completion of term |